Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Guardant Health , Inc. (NASDAQ:GH) director Tariq Musa recently sold shares of the company’s common stock, according to a recent filing with the Securities and Exchange Commission. On February 20, Musa sold 116 shares at a price of $48.33 per share, totaling $5,606. Following this transaction, Musa retains ownership of 3,078 shares in the company. The sale comes as the stock has experienced significant momentum, posting an impressive 89% return over the past year and a 40% gain year-to-date, according to InvestingPro data.
The sale was conducted under a pre-arranged trading plan, often utilized by insiders to avoid potential conflicts of interest when buying or selling stock. Guardant Health, based in Palo Alto, California, is a leading provider of oncology-focused diagnostic tests. The $5.3 billion company has demonstrated strong growth with revenue increasing 31% over the last twelve months, maintaining healthy liquidity with a current ratio of 4.7. InvestingPro analysis indicates the stock is currently trading above its Fair Value, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US stocks.
In other recent news, Guardant Health reported fourth-quarter earnings for 2024 that exceeded expectations, with total revenues reaching $202 million, surpassing consensus estimates by 7%. The company’s gross margin was reported at 62%, which also exceeded expectations. Guardant Health’s financial performance was strengthened by growth in clinical and biopharma test volumes, as well as prior period cash collections. Looking ahead, the company has provided guidance for 2025, projecting revenues between $850 million and $860 million, with a significant increase anticipated in test volumes and revenue, especially for their Shield product. Analysts from Canaccord, BTIG, Bernstein, Citi, and BofA have all raised their price targets for Guardant Health to $60, reflecting a positive outlook on the company’s future performance. Canaccord and BTIG analysts maintained a Buy rating, highlighting the company’s strong market position and potential growth opportunities. Meanwhile, Citi analysts noted the company’s increased clinical volumes and biopharma volumes, which saw year-over-year growth. Guardant Health also anticipates a 15-16% year-over-year revenue increase in 2025, with significant growth expected in their oncology segment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.